A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

Phase 2Active Not RecruitingNCT05857930

OM Pharma SA296 enrolled

Overview

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing

This study is a 12-months phase 2, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of daily treatment with OM-85 compared to placebo, when given on top of standard of care treatment, in reducing wheezing/asthma like episodes (WEs) during the 6-month treatment period in children aged 6 months to 5 years with previous recurrent WEs. Patients will be randomized in a 1:1 ratio to OM-85 or placebo. The study consists of screening period (Day -20 to Day -1), a treatment period of 6 months, and an observational period of 6 months without treatment. Thus, the total duration of the study for each patient will be 12 months (±10 days) + up to 20 days for screening.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

296

Conditions

Recurrent Wheezing Wheezing Lower Respiratory Illness

Interventions

OM-85DRUG

OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.

PlaceboDRUG

Placebo capsule contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 72 Months

Medical Language ↔ Plain English

Inclusion Criteria: Subjects who meet all the following criteria will be included in the study: * Children of either gender, aged between 6 and 72 months (5 years inclusive). * Children with recurrent wheezing: * For ICS/LTRA naïve patients or intermittent users (patients using ICS treatment only during an upper RTI to prevent WE): ≥2 WEs including at least 1 severe episode (i.e., treated with OCS OR having triggered an ED visit/hospitalization), OR ≥3 WEs including at least one that triggered an unscheduled physician visit, in the 12 months prior to enrollment. * For ICS/LTRA daily users: ≥1 severe WE (i.e., treated with OCS OR having triggered an ED visit/hospitalization) OR ≥2 WEs including at least one that triggered an unscheduled physician visit, as reported by parents or LAR of subject (i.e., guardians), in the 12 months prior to enrollment, while being on their daily controller therapy (at current dose or higher). * Up-to-date vaccination status as per applicable State or country Vaccination Requirements for school/day-care entry. * Parents or LAR have provided the appropriate written informed consent. Written informed consent must be provided before any study-specific procedures are performed including screening procedures. Note: If a subject is experiencing respiratory symptoms at time of screening, he/she could only be randomized once symptoms have resolved for at least one week. Exclusion Criteria: * Known anatomic alterations of the respiratory tract. * Wheezing documented to be caused by gastroesophageal reflux. * Other known chronic respiratory diseases (e.g., tuberculosis or cystic fibrosis). * Any known autoimmune disease. * Known human immunodeficiency virus (HIV) infection or any known type of congenital or iatrogenic immune deficiency (including immunoglobulin (Ig) A deficiency). * Known acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal function abnormalities. * Children born prematurely i.e., before 34 weeks of gestational age. * Children with an abnormally low or high weight for their age and height, if this would not allow safe completion of the clinical study in the opinion of the investigator. * Any known neoplasia or malignancy. * Treatment with the following medications: * Systemic corticosteroids within 4 weeks before study enrollment. * Previous and/or concomitant immunosuppressants, immunostimulants, or gamma globulins within 6 months before study enrollment. * Any major surgery within the last 3 months prior to study enrollment or planned during the study duration. * Known allergy or previous intolerance to investigational drug. * Any other clinical conditions, which in the opinion of the Investigator, would not allow safe completion of the clinical study. * Other household members have previously been randomized in this clinical study and have not completed their 6-month treatment period. * Inability to comply with the study requested visit schedule (e.g., expected relocation within 12 months of the screening for the study). * Currently enrolled in or has completed any other investigational device or drug study \<30 days prior to screening or receiving other investigational agent(s). Note: Subjects with past, present, or at risk of COVID-19 should not be excluded from the study.

Locations (37)

Outcomes

Primary Outcomes

Rate of Wheezing/Asthma like episodes (WEs)

To assess the efficacy of OM-85 in reducing the rate of WEs compared to placebo during the 6-month Treatment period in children aged 6 months to 5 years with previous recurrent WEs.

Time frame: 6 Months

Secondary Outcomes

Rate of severe WEs

To assess the efficacy of OM-85 in reducing the rate of severe WEs compared to placebo during the 6-month Treatment period.

Time frame: 6 Months

Number of WE requiring oral corticosteroid (OCS) treatment during 6-month treatment period

To assess the efficacy of OM-85 in reducing the use of oral corticosteroids for WEs compared to placebo during the 6-month Treatment period.

Time frame: 6 Months

Number of days with WEs

To assess the efficacy of OM-85 to decrease the cumulative number of days with WEs compared to placebo during the 6-month Treatment period.

Time frame: 6 Months

Rate of WEs and severe WEs

To assess the efficacy of OM-85 compared to placebo in reducing the rate of WEs and severe WEs during the 6-month Observational period.

Time frame: From Month 6 up to Month 12

Number of WE requiring OCS treatments during 6-month observational period

To assess the efficacy of OM-85 in reducing the use of oral corticosteroids for WEs vs. placebo during the 6-month observational period.

Time frame: From Month 6 up to Month 12

Duration in days of WEs and severe WEs

To assess the efficacy of OM-85 compared to placebo in reducing the duration of WEs and of severe WEs during the 6-month Treatment period and the 6-month Observational period.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Arizona Medical Clinic

Phoenix, Arizona, United States

Phoenix Children's Hospital

Phoenix, Arizona, United States

The University of Arizona Medical Center - University Campus

Tucson, Arizona, United States

Arkansas Children's Hospital Research Institute

Little Rock, Arkansas, United States

Kern Research Inc.

Bakersfield, California, United States

Hoag Health Center Foothill Ranch

Foothill Ranch, California, United States

UCSF Benioff Children's Hospital Oakland Primary Care Clinic

Oakland, California, United States

Allergy & Asthma Medical Group and Research (AAMGRC) - Allergy, Asthma and Immunology

San Diego, California, United States

Rady Children's Hospital

San Diego, California, United States

Children's Hospital Colorado - Pediatric Heart Lung Center - Pediatrics

Aurora, Colorado, United States

...and 27 more locations